mRNA: Therapeutics and Global Markets
Report Highlights
The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable or slightly decline to $7.69 billion by the end of 2030, at a compound annual growth rate (CAGR) of -0.04% during the forecast period of 2025 to 2030.
Report Includes
- 19 data tables and 71 additional tables
- An overview and analysis of the global markets for messenger RNA (mRNA)-based therapeutics
- Analyses of the global market trends, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
- Estimates of the size and revenue prospects for the global mRNA market, along with a market share analysis by disease type, indication, and region
- Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations and the impacts of macroeconomic variables
- Insights derived from Porter’s Five Forces model, global supply chain and PESTLE analyses
- Patent analysis, featuring key granted and published patents
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings and consumer attitudes
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Moderna Inc., Pfizer Inc., BioNTech SE, Merck & Co., and Sanofi
Report Scope
The report analyzes the global market for mRNA therapeutics. It includes global revenue ($ millions) for the base year of 2024, estimated data for 2025 and projected compound annual growth rates (CAGRs) through 2030. The report examines the different types of mRNA and their applications for therapeutic use. It also focuses on mRNA patents and clinical trials and examines the trends affecting the market during the forecast period. The report profiles the leading companies and their strategic alliances and partnerships. The report segments the global market into North America, Europe, Asia-Pacific (APAC) and the Rest of the World (RoW).
Frequently Asked Questions (FAQs)
- Rising number of pandemics and epidemic outbreaks.
- Increasing awareness regarding vaccination.
- Rise in investments related to mRNA therapeutics research.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2024 |
| Forecast period considered | 2025-2030 |
| Base year market size | $8.36 Billion |
| Market size forecast | $7.69 Billion |
| Growth rate | CAGR of -0.04% for the forecast period of 2025-2030 |
| Units considered | $ Millions |
| Segments covered | Disease Type, Indication, and Region |
| Regions covered | North America, Europe, Asia-Pacific, and Rest of the World |
| Key Market Drivers |
|
| Companies studied |
|
Report Highlights
The global market for mRNA therapeutics is expected to decline from $33 billion in 2023 to $21 billion by the end of 2028, at a compound annual growth rate (CAGR) of -8.6% during the forecast period of 2023-2028.
Report Includes
- 37 data tables and 27 additional tables
- An overview of the global market related to mRNA therapeutics
- In-depth analysis of global market trends, featuring historical revenue data for 2021 and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market and revenue growth prospects specific to mRNA therapeutics, accompanied by a market share analysis by therapeutic type and geographical region
- Coverage of the pandemic threats, therapeutic developments, and new technologies in the market
- Discussion of the advantages of mRNA over protein- and DNA-based delivery systems, demographic and economic trends, and outlook for the mRNA therapeutics market
- Information on prophylactic vaccines, vaccine discovery and development, and R&D activities
- Analysis of the various therapeutics as well as promising vaccines intended for the prevention and treatment of chronic and infectious diseases
- Assessment of regulatory structure, pricing and reimbursement scenarios, the pipeline for new molecules and therapeutics
- Market share analysis of the key companies and mergers & acquisitions, joint ventures, collaborations, and partnerships
- Profiles of leading market participants
Report Highlights
The global market for mRNA therapeutics should grow from $46.7 billion in 2021 to $101.3 billion by 2026, at compound annual growth rate (CAGR) of 16.8% for the period of 2021-2026.
Report Includes
- 32 data tables and 32 additional tables
- An overview of the global market for mRNA therapeutics
- Analyses of global market trends with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the major developments, pandemic threats, therapeutic developments, and technological developments of the mRNA therapeutics market
- Discussion on significant advantages of mRNA over protein or DNA-based delivery systems and description of demographic and economic trends, and outlook of the mRNA therapeutics market
- Evaluation of current market size and forecast and information on prophylactic vaccines, vaccine discovery and development, and R&D activities
- Analysis of the various innovative therapeutics as well as new promising vaccines intended for the prevention and treatment of various chronic and infectious diseases
- Assessment of regulatory structure, pricing and reimbursement scenario, and pipeline analysis of the new molecules & therapeutics
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Comprehensive company profiles of major players of the industry, including Amgen Inc., Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson and Novartis